Waters Corporation Raises Full-Year Outlook After Q2 Beat Highlights Strength in Acquired Business

Waters Corporation (NYSE: WAT) reported second-quarter 2026 results on August 4, 2026, beating expectations and lifting its full-year outlook after delivering stronger-than-expected performances across both organic operations and its newly acquired Biosciences & Diagnostic Solutions businesses.

Q2 Performance Tops Guidance

Waters posted total reported revenue of $1.645 billion in Q2 2026, surpassing the high end of its guidance range. Organic revenue reached $828 million, rising 7% year-over-year as reported and 9% in constant currency, powered by 8% instrument growth and double-digit chemistry consumables demand across both pharmaceutical and analytical & general (A&G) markets. Revenue from its newly acquired Biosciences & Diagnostic Solutions unit came in at $817 million—$15 million above the prior callout—marking a 4% increase versus the prior-year comparable period. These gains reflect successful execution under the company’s 180-day growth revitalization plan. (Waters earnings release, Aug 4)

GAAP Loss Offsets Adjusted Earnings Gain

On a GAAP basis, Waters reported a diluted loss per share of $1.39, a decline from the $2.47 EPS in Q2 of 2025, attributable to acquisition-related purchase accounting charges, including amortization of acquired intangibles and inventory step-up. However, adjusted EPS rose to $3.05—hitting the high end of the company’s guidance range and up from $2.95 in Q2 2025. (Waters earnings release, Aug 4)

Full-Year Guidance Raised Across the Board

buoyed by broad-based strength and momentum in integration, Waters raised all components of its full-year 2026 guidance. It now expects:

• Organic constant-currency revenue growth of 7%–9%, with reported organic revenue anticipated between $3.370 billion and $3.431 billion.
• Acquired business reported revenue of approximately $3.045 billion on an owned‑period basis.
• Total reported revenue ranging from $6.415 billion to $6.476 billion.
• Adjusted EPS of $14.45 to $14.65, reflecting 10%–12% y/y growth (or 12%–14% in constant currency).

For Q3, the company targets organic constant-currency revenue growth of 8%–10%, with organic reported revenue expected between $850 million and $867 million, and acquired business revenue of approximately $895 million. (Waters earnings release, Aug 4)

Integration Momentum and Market Recovery Accelerate Growth

CEO Udit Batra emphasized that the quarter’s outperformance stemmed from effective integration of recent acquisitions and a broadening market recovery. He noted that previously lagging end-markets have now returned to growth and that the combined company is better positioned with a broader portfolio, a larger installed base, and more visible growth catalysts than at any point recently. (Waters earnings release, Aug 4)

Significance for Investors

Waters’ Q2 results provide solid evidence that its strategy to integrate the Biosciences & Diagnostic Solutions business is bearing fruit faster than anticipated, helping to diversify revenue and reinforce long-term growth prospects. The raised guidance gives investors increased visibility into revenue and earnings through year-end, underscoring momentum across both legacy and acquired operations.

While the GAAP loss reflects accounting impacts of the acquisition, the strong adjusted EPS and higher guidance suggest operating fundamentals remain robust. Key upcoming milestones to monitor include actual performance in Q3, continued integration efficiency, and progress in sustaining consumables growth in core segments.